Skip to main content
. 2020 May 4;83(1):288–292. doi: 10.1016/j.jaad.2020.04.143

Fig 1.

Fig 1

University of Miami clinical considerations for managing patients on systemic immunosuppressive or biologic therapy, or both (SIBT), during COVID-19 pandemic. CDC, Centers for Disease Control and Prevention; DMARDs, disease-modifying antirheumatic drugs: azathioprine, cyclosporine, methotrexate; SOB, shortness of breath.